The medicines regulator Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the Covid-19 vaccine developed by the Swedish-British company.
While the supervisory authority saw conclusive results from studies involving many participants to approve two other coronavirus vaccines, the same could not be said for the Oxford-AstraZeneca shot, Swissmedic director Raimund Bruhin told the CH Media group of newspapers on Thursday.
But this did not mean that he believes the vaccine is a poor one.
“We are only saying that the company has not yet been able to prove to us that it is a good vaccine,” said Bruhin.
The approvals process, he added, was about hard data and facts. Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing, and remains in regular contact with the makers of the vaccine.
Other countries, such as the United Kingdom, have been administering the AstraZeneca vaccine for over three months – although several nations have halted vaccinations in recent days over isolated cases of blood-clotting. The European Medicines Agency has said the benefits of the Oxford-AstraZeneca jab greatly outweigh the risks and on Thursday will issue a report on its investigation into cases of blood clots.
Switzerland has ordered more than 35 million doses of Covid-19 vaccines from five manufacturers. To date Swissmedic has approved shots developed by Pfizer/BioNTech and Moderna. Roughly 4% of the population has been vaccinated so far, but delays in approval and delivery have slowed the roll-out process.
Popular Stories
More
Foreign affairs
European nations snub Swiss-made weapons over Ukraine restrictions
This content was published on
The man who injured three children on Tuesday has been detained in pre-trial custody after a request by the public prosecutor’s office.
UN and global ski federation sign climate change agreement
This content was published on
The UN and the International Ski and Snowboard Federation want to draw attention to the effects of climate change on winter sports.
Swiss initiative wants to boost security of medical supplies
This content was published on
A people’s initiative calling for Switzerland to boost the development, production and storage of drugs has been submitted in Bern.
Public prosecutor wants custody for Zurich knife attacker
This content was published on
The Zurich public prosecutor's office has requested that the man who attacked and injured three children with a knife in Zurich on Tuesday be remanded in custody.
This content was published on
Swiss judges want to dissolve the traditional link between parties and court members, including mandatory contributions to a political party.
A full-time workload increases risk of cancer, says Swiss study
This content was published on
Full-time workers have an increased risk of cancer, say researchers from the University of Fribourg. The reasons for this are unclear.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland could sell or give away AstraZeneca doses if regulator dithers
This content was published on
A lack of green light from medicines regulator Swissmedic could see 5.3 million doses ordered by Switzerland sent elsewhere.
This content was published on
Media reports indicate that vaccinating everyone who wants to by summer relies on meeting ambitious vaccine delivery targets in spring.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.